



HAL
open science

Relationship between obesity and ventilator-associated pneumonia: a post-hoc analysis of the NUTRIREA2 trial.

Saad Nseir, Amélie Le Gouge, Olivier Pouly, Jean-Baptiste Lascarrou, Jean-Claude Lacherade, Jean-Paul Mira, Emmanuelle Mercier, Pierre-Louis Declercq, Michel Sirodot, Gaël Piton, et al.

► To cite this version:

Saad Nseir, Amélie Le Gouge, Olivier Pouly, Jean-Baptiste Lascarrou, Jean-Claude Lacherade, et al.. Relationship between obesity and ventilator-associated pneumonia: a post-hoc analysis of the NUTRIREA2 trial.. Chest, 2021, Chest, 10.1016/j.chest.2021.01.081 . hal-04257556

HAL Id: hal-04257556

<https://hal.univ-lille.fr/hal-04257556v1>

Submitted on 22 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Relationship between obesity and ventilator-associated pneumonia: a post-hoc analysis of the NUTRIREA2 trial

Saad NSEIR^{1,2}, PhD, Amélie LE GOUGE³, PhD, Olivier POULY¹, MD, Jean-Baptiste Lascarrou⁴, MD, Jean-Claude Lacherade⁵, MD, Jean-Paul Mira⁶, PhD, Emmanuelle Mercier⁷, MD, Pierre-Louis Declercq⁸, MD, Michel Sirodot⁹, MD, Gaël Piton¹⁰, PhD, François Tinturier¹¹, MD, Elisabeth Coupez¹², MD, Stéphane Gaudry^{13,14}, PhD, Michel Djibré¹⁵, MD, Didier Thevenin¹⁶, MD, Malika Balduyck¹⁷, PhD, Jean REIGNIER⁴, PhD, on behalf of the NUTRIREA2 study group

¹Médecine Intensive-Réanimation, CHU Lille, F-59000 Lille, France

²Inserm U1285, Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France

³Inserm CIC 1415, CHU Tours, Tours, France

⁴Medecine Intensive Réanimation, Centre Hospitalier Universitaire de Nantes, Nantes, France ; Université de Nantes, Nantes, France

⁵Médecine Intensive Réanimation, Centre Hospitalier Départemental de la Vendée, La Roche-sur-Yon, France.

⁶Medical Intensive Care Unit, Cochin University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

⁷Médecine Intensive Réanimation, Hôpital Bretonneau, CHU Tours, Tours, France.

⁸Médecine Intensive Réanimation, Hôpital de Dieppe, Dieppe, France.

⁹Medical-Surgical Intensive Care Unit, Centre Hospitalier Annecy-Genevois, Metz-Tessy, Pringy, France.

¹⁰Medical Intensive Care Unit, CHRU Besançon ; and EA3920, Université de Franche Comté, Besançon, France.

¹¹Surgical Intensive Care Unit, CHU Amiens Picardie, Amiens, France.

¹²Intensive Care Unit, Hôpital Gabriel Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand, France.

¹³Service de Réanimation Médico-Chirurgicale, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France.

¹⁴INSERM, UMR_S1155, Remodeling and Repair of Renal Tissue, Hôpital Tenon, Paris, Paris, France.

¹⁵Service de Médecine intensive Réanimation, Hôpital Tenon, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

¹⁶Medical-Surgical Intensive Care Unit, Centre Hospitalier Docteur Schaffner, Lens, France.

¹⁷Centre de Biologie Pathologie, CHU Lille, F-59000, Lille, France.

Word count: abstract 294, main text 1962

Corresponding author:

Pr. Saad Nseir, Critical Care Center, CHU Lille, F-59000 Lille

Tel: 03.20.44.40.84

Email: s-nseir@chru-lille.fr

ABSTRACT

Background

Patients with obesity are at higher risk for community-acquired and nosocomial infections. However, no study has specifically evaluated the relationship between obesity and ventilator-associated pneumonia (VAP).

Research question

Is obesity associated with increased incidence of VAP?

Study design and methods

Post-hoc analysis of the NUTRIREA-2 open-label RCT, performed in 44 French ICUs. Adults receiving invasive mechanical ventilation and vasopressor support for shock, and parenteral nutrition or enteral nutrition were included. Obesity was defined as body mass index (BMI) \geq 30 kg/m² at ICU admission. VAP diagnosis was adjudicated by an independent blinded committee, based on all available clinical, radiological, and microbiological data. Only first VAP episodes were taken into account. Incidence of VAP was analyzed using Fine and Gray model, with extubation, and death as competing risks.

Results

699 (30%) of the 2325 included patients had obesity. 224 first VAP episodes were diagnosed (60, and 164 in obese, and non-obese groups; respectively). The incidence of VAP at day 28 was 8.6% vs 10.1% in the two groups (HR: 0.85, (95% CI 0.63-1.14), p=0.26). After adjustment on gender, McCabe score, age, anti-ulcer treatment, and SOFA at randomization, the incidence of VAP remained non-significant between obese and non-obese patients (HR 0.893 (95% CI 0.66-1.2), p=0.46). Although no significant difference was found in duration of mechanical ventilation, and ICU length of stay; 90-day mortality was significantly lower in

obese than in non-obese patients (272 of 692 (39.3%) patients vs 718 of 1605 (44.7%), $p=0.02$). In a sub-group of patients ($n=123$) with available pepsin, and alpha-amylase measurements, no significant difference was found in rate of abundant microaspiration of gastric contents, or oropharyngeal secretions between obese and non-obese patients.

Interpretation

Our results suggest that obesity has no significant impact on the incidence of VAP.

Clinical trial registration: Not applicable

Key words:

Obesity, intubation, mechanical ventilation, microaspiration, pneumonia

Abbreviations:

BMI, body mass index; HR, hazard ratio; ICU, intensive care unit; IQR, interquartile range;

SAPS, simplified acute physiology score; VAP, ventilator-associated pneumonia

INTRODUCTION

The prevalence of obesity is high in the ICU, ranging from 19% up to 66% of critically ill patients^{1,2}. Obesity appears to be associated with lower mortality in the critically ill patients, but increases the risk of complications in several organ systems³. Previous studies have suggested a high incidence of community-acquired and healthcare-associated infections in obese patients⁴⁻⁷. Several explanations were suggested for the high incidence of infection in obese patients, including comorbidities, frequent hospitalization, changes in gut microbiota, chronic inflammation, and altered immunity^{3,6,8,9}. The interaction between adipocytes and immune cells could be responsible for dysregulation of both innate and adaptive immunity¹⁰. In addition, adipose tissue produces inflammatory mediators resulting in chronic inflammation and elevated baseline CRP levels in obese patients^{10,11}.

Previous studies reported higher rates of hospital-acquired and surgical site infections^{4,5,12,13}. Similarly, in a post-hoc analysis of a large international database, obesity was found to be associated with higher incidence of ICU-acquired infections. However, no information on ventilator-associated pneumonia (VAP) incidence was given in that study⁷.

VAP is the most common ICU-acquired infection¹⁴. Although mortality attributable to VAP is a matter for debate¹⁵, this infection is associated with increased duration of mechanical ventilation, length of ICU stay and cost¹⁶. Better understanding of pathophysiology and risk factors for VAP could be helpful to improve its prevention and treatment¹⁷.

To our knowledge, no study has specifically evaluated the relationship between obesity and VAP. However, as discussed above, obesity could be associated with increased

risk for infection. In addition, other specific factors might favor VAP occurrence in obese patients, such as atelectasis, and difficult airway management ³.

Therefore, we perform this post-hoc analysis of the NUTRIREA 2 study to evaluate the relationship between obesity and VAP. The primary aim was to determine the impact of obesity on VAP incidence. Secondary objectives were to evaluate the relationship between obesity, and early-onset VAP, duration of mechanical ventilation, ICU length of stay, and 90-day mortality. The impact of obesity on microaspiration of gastric and oropharyngeal secretions was also evaluated in a subgroup of study patients.

STUDY DESIGN AND METHODS

This was a post-hoc analysis of the randomized controlled multicenter open-label NUTRIREA2 study (ClinicalTrials.gov, identifier NCT01802099), performed in 44 French ICUs. Adults (18 years or older) receiving invasive mechanical ventilation, vasopressor support for shock, and parenteral or enteral normocaloric (20-25 kcal/kg per day) nutrition, within 24 h after intubation were included ^{18,19}.

The study protocol was approved by the ethics committee of the French Intensive Care Society and appropriate French authorities (Comité de Protection des Personnes de Poitiers). According to French law, because the treatments and strategies used in the study were classified as standard care, there was no requirement for signed consent, but the patients or next of kin were informed about the study before enrolment and confirmed this fact in writing.

All patients included in the NUTRIREA2 study were eligible for this study. Patients with no information on body mass index (BMI) were excluded from the current study.

Definitions

The primary outcome was the incidence of VAP. Secondary outcomes were the incidence of early-onset VAP, duration of mechanical ventilation, ICU length of stay, 90-day mortality rate, and the incidence of abundant microaspiration of gastric contents or oropharyngeal secretions.

Obesity was defined as body mass index (BMI) ≥ 30 kg/m² at ICU admission. VAP diagnosis was adjudicated by an independent blinded committee, based on all available clinical, radiological, and microbiological data. Early-onset VAP was defined as VAP occurring before day 5 after starting invasive mechanical ventilation ¹⁸. Abundant microaspiration of gastric contents was defined by the presence of pepsin at significant concentration (> 200 ng

/ ml) in >30% of tracheal aspirates^{20,21}. Abundant microaspiration of oropharyngeal secretions was defined by the presence of amylase at significant concentration (> 1685 IU / ml) in >30% of tracheal aspirates^{20,21}. Methods used for pepsin, and alpha-amylase measurements, collection of tracheal aspirates, and VAP prevention were described elsewhere²¹.

Primary and secondary outcomes, except abundant microaspiration, were evaluated in all study patients. The impact of obesity on abundant microaspiration was evaluated in a subgroup of patients with available measurement of pepsin or alpha-amylase (n=123) in tracheal aspirates collected during the 48h after randomization. These patients were included in a planned ancillary study, which evaluated the impact of enteral nutrition on microaspiration²¹.

Statistical analysis

Baseline characteristics were compared according to obesity status using student t-tests or Wilcoxon non-parametric tests for continuous variables and χ^2 or Fisher's exact tests for categorical variables.

Incidence of VAP was analyzed using Fine and Gray competing risk model²², with extubation and death as competing risks. An adjusted analysis was performed including variables collected at ICU admission with $p < 0.2$ in the univariate analysis. The choice of adjustment variables was also based on scientific knowledge and considered potential collinearity.

Incidence of early VAP was analyzed using Fine and Gray competing risk model with extubation and death as competing risks. The rate of patients with abundant microaspiration of gastric contents, or abundant microaspiration of oropharyngeal secretions was compared

between study groups using Chi-square. The related quantitative parameters were studied using Wilcoxon non-parametric tests. Death at day 90 was analyzed using Chi-square. Incidence of ICU discharge alive and extubation were analyzed using a Fine and Gray competing risk model with death as a competing risk.

SAS (version 9.4), and R (version 3.6.3) were used for statistical analyses.

RESULTS

A total of 2410 patients were randomized in the NUTRIREA2 trial, 85 (4%) patients were excluded because BMI was not available. Among the 2325 patients included in this post-hoc analysis, 699 (30.1%) had obesity (Figure 1). Pepsin and alpha-amylase were quantitatively measured in 852 tracheal aspirates, collected from 123 patients.

Patient characteristics

At ICU admission, female gender, age, McCabe score, Knaus score, acute illness at ICU admission and pre-existing illness at ICU admission significantly differed between obese and non-obese patients (Table 1).

At randomization, positive end expiratory pressure (PEEP), FiO₂, renal replacement therapy, insulin use, antiulcer medication, glucose, creatinine, albumin levels, and SOFA score significantly differed between obese and non-obese patients (Table 2).

During the 7 days following randomization, daily calorie intake (median (IQR) 19 (15, 21) vs 19.2 (15.8, 22.2), $p=0.01$) was significantly lower, and incidence of patients with at least one vomiting (24% vs 19.3%, HR 1.29 (95% CI 1.07-1.54), $p=0.008$) was significantly higher in obese than in non-obese patients; respectively.

Outcomes

A total of 224 first VAP episodes were diagnosed in study patients (60, and 164 episodes in obese and non-obese patients; respectively). No significant difference was found in the incidence of VAP between obese and non-obese patients at day 28 (8.6% vs 10.1%; HR 0.85 (95% CI 0.63-1.140), $p=0.26$) (Figure 2). After adjustment on gender, McCabe score, age, anti-ulcer treatment, and SOFA at randomization, the incidence of VAP remained non-significant between obese and non-obese patients (HR 0.89 (95% CI 0.66-1.20), $p=0.46$).

A sensitivity analysis was performed for center effect. Similar results were found on the primary outcome (HR: 0.85, CI95%: [0.60; 1.19], p=0.33).

A total of 46 first early-onset episodes were diagnosed (12, and 34 in obese and non-obese patients). No significant difference was found in the incidence of early-onset VAP at day 28 between the two groups (1.7% vs 2.1%, HR 0.82 (95% CI 0.43-1.58), p=0.55).

Although the incidence of extubation at day 28 (66.1% vs 65.2% (HR 0.99 (95% CI 0.89-1.08), p=0.71) (Figure 3), and ICU discharge alive at day 28 (58.4% vs 57.9% (HR 0.99 (95% CI 0.89-1.09), p=0.79) (Figure 4) were not significantly different between obese and non-obese patients; 90-day mortality was significantly lower in obese than in non-obese patients (Table 3).

The distribution of study patients and patients with VAP, based on BMI, is presented in table 4.

No significant difference was found between obese in non-obese patients in the percentage of patients with abundant microaspiration of gastric secretions (15 of 49 (30.6%) patients vs 14 of 74 (18.9%), p=0.13) or oropharyngeal secretions (31 of 49 (63.3%) patients vs 48 of 74 (64.9%), p=0.86).

DISCUSSION

The main results of our study are the following: the incidence of VAP was not significantly different between obese and non-obese patients. Similarly, no significant difference was found in the incidence of early-onset VAP between obese and non-obese patients. Obesity had no significant impact on duration of mechanical ventilation, length of ICU stay, or microaspiration of gastric contents, or oropharyngeal secretions. 90-day mortality was significantly lower in obese than in non-obese patients.

To our knowledge, our study is the first to evaluate the relationship between obesity and VAP. The strengths of our study are multicenter design, large number of included patients, and stringent criteria used for VAP definition. However, several limitations should also be outlined. First, our results only apply to patients with shock. Whether obesity is associated with VAP in critically ill patients without shock is still to be investigated. Second, some risk factors for VAP such as antimicrobial use, head-of-bed elevation, and tracheal cuff pressure were not assessed. Third, microaspiration was only evaluated in a small subgroup of patients. However, the impact of obesity on microaspiration was a secondary objective of our study. Fourth, center effect was not taken into account in the analyses. However, we performed a sensitivity analysis for center effect, and similar results were found regarding primary outcome (online supplementary material). In addition, the diagnosis of VAP was adjudicated by an independent blinded committee, which might have also allowed adjustment for center effect. Finally, our study was a post-hoc analysis of the NUTRIREA2 database.

At least two explanations could be provided for the absence of significant impact of obesity on VAP incidence. First, several significant differences were identified between

obese and non-obese patients and could have influenced our results, including gender, comorbidities, and acute illness at ICU admission; PEEP level, FiO₂, renal replacement therapy, insulin use, antiulcer treatment, glucose, creatinine, and albumin level at randomization; daily-calorie intake, and vomiting during the 7 days following randomization. However, after adjustment for several confounders, no significant relationship was found between obesity and VAP. Second, in spite of the strong rationale suggesting that obesity could be associated with high incidence of VAP, obese patients could be at similar risk for developing VAP as non-obese patients. One could argue that the incidence of important risk factors for VAP, such as long duration of mechanical ventilation, tracheobronchial colonization, and microaspiration of contaminated secretions is probably similar in obese and non-obese patients. Our findings on the absence of significant impact of obesity on microaspiration of gastric contents, or oropharyngeal secretions are in line with this possibility. In a case-control matched study, Frat et al.²³ aimed to determine the impact of severe obesity (BMI ≥ 35 kg/m²) on mortality and morbidity. A lower, but not statistically significant, incidence rate of ventilator-associated pneumonia (VAP) was found (7.8 vs 12.4 VAP episodes per 1000 mechanical ventilation days in obese and non-obese patients; respectively). Our group performed a case-control matched study to determine the accuracy of leptin in predicting VAP occurrence²⁴. No significant difference in BMI, or in obesity rate, was found between patients with VAP and their controls.

Our results also suggest that obesity is associated with reduced risk for 90-day mortality rate. This result is in line with recent studies, and confirms the “obesity paradox”. Several mechanisms were suggested to explain this phenomenon. Adipose tissue may provide energy and lipid soluble nutrients during highly metabolic states, and immunomodulatory effects of substances secreted by fat cells might attenuate the

inflammatory response during acute illness and improve survival^{9,11,25}. Additionally, better exposure to adequate healthcare was also reported in obese patients³. However, 90-day mortality was a secondary outcome in our study, and no adjustment was performed for potential confounders.

CONCLUSIONS

Our results suggest that obesity is not associated with increased risk for VAP. Although obesity was associated with reduced 90-day mortality rate, no significant association was found between obesity and duration of mechanical ventilation, length of ICU stay, or microaspiration of gastric and oropharyngeal secretions.

Take-Home Points

Study question: Is obesity associated with increased risk for ventilator-associated pneumonia?

Results: In critically ill patients, receiving invasive mechanical ventilation for >48h, obesity is not associated with increased incidence of ventilator-associated pneumonia.

Interpretation: Obese patients are not at increased risk for ventilator-associated pneumonia.

ACKNOWLEDGEMENTS

Guarantor

SN

Authors' contribution:

SN, AL, OP, and JR designed the study. AL performed the statistical analyses. All authors collected study data. The first draft was written by SN, AL, and OP. All authors participated in writing, and revising the manuscript.

Financial support:

None

Declaration of interests

SN received personal fees from MSD, Bio Rad, BioMérieux, Gilead, and Pfizer. All other authors declare no competing interests.

Data Sharing

All data needed to evaluate the conclusions in this Article are present and tabulated in the main text. For individual de-identified raw data that underlie the results reported in this article, please contact the corresponding author.

In addition to the authors, the NUTRIREA2 study group includes the following collaborators:

Hospital	First name	Last name	email
Annecy	Michel	Sirodot	msirodot@ch-annecygenevois.fr;
Bordeaux	Hoang-Nam	Bui	hoang-nam.bui@chu-bordeaux.fr
Chartres	Olivier	Gontier	ogontier@ch-chartres.fr;

Dijon	Jean-Pierre	Quenot	jean-pierre.quenot@chu-dijon.fr;
Grenoble	Carole	Schwebel	CSchwebel@chu-grenoble.fr;
Lyon Croix Rousse	Véronique	Leray	veronique.leray@chu-lyon.fr;
Melun	Nathalie	Rolin	nathalie.rolin@ch-melun.fr;
Montauban	Frédéric	Bellec	f.bellec@ch-montauban.fr;
Montreuil	Vincent	DAS	vincent.das@chi-andre-gregoire.fr;
Nantes réa chir	Antoine	Roquilly	Antoine.ROQUILLY@chu-nantes.fr;
Nantes rea chir nord	Laurent	Brisard	brisard.laurent@neuf.fr ;
Orléans	Thierry	Boulain	thierry.boulain@chr-orleans.fr;
Paris APHP Bicêtre	Nadia	Anguel	nadia.anguel@bct.aphp.fr;
Paris Foch	Jérôme	Devaquet	j.devaquet@hopital-foch.org;
Paris APHP Garches	Virginie	Maxime	virginie.maxime@rpc.aphp.fr;
Paris St Denis	Daniel	Da Silva	daniel.silva@mac.com;
Paris APHP saint-louis	Emmanuel	Canet	Emmanuel.canet@chu-nantes.fr
Paris APHP st Antoine	Bertrand	Guidet	bertrand.guidet@sat.aphp.fr;
Paris St Joseph	Charles	Grégoire	charles.gregoire@gmail.com;
Pointe-à-Pitre	Frédéric	Martino	frederic.martino@chu-guadeloupe.fr;
Poitiers réa med	Delphine	Chatelier	d.chatelier@chu-poitiers.fr;
St Malo	Vlad	Botoc	v.botoc@ch-stmalo.fr;
Saint-Etienne	Guillaume	Thiery	guillaume.thiery@chu-st-etienne.fr;
Strasbourg HC	Christine	Kummerlen	Christine.KUMMERLEN@chru- strasbourg.fr;
Strasbourg Hautepierre	J-Etienne	Herbrecht	Francis.Schneider@chru- strasbourg.fr;
Tours réa med	Emmanuelle	MERCIER	emercier@med.univ-tours.fr;
Rodez	Philippe	LETOCART	P.LETOCART@ch-rodez.fr;
Angers	Pierre	ASFAR	PiAsfar@chu-angers.fr;
Mulhouse	Frederique	GANSTER	gansterf@ch-mulhouse.fr;
Beauvais	Richecoeur	Jack	j.richecoeur@ch-beauvais.fr
Lyon E.Herriot	Argaud	Laurent	laurent.argaud@chu-lyon.fr
Lille	Zerimech	Farid	Farid.zerimech@chru-lille.fr
Lille	Maboudou	Patrice	Patrice.maboudou@chru-lille.fr

REFERENCES

1. Decruyenaere A, Steen J, Colpaert K, Benoit DD, Decruyenaere J, Vansteelandt S. The obesity paradox in critically ill patients: a causal learning approach to a casual finding. *Crit Care*. 2020;24(1):485.
2. Jagan N, Morrow LE, Walters RW, et al. Sepsis and the Obesity Paradox: Size Matters in More Than One Way. *Crit Care Med*. 2020;48(9):e776-e782.
3. Schetz M, Jong A De, Deane AM, et al. Obesity in the critically ill: a narrative review. *Intensive Care Med*. 2019;45(6):757–769.
4. Dossett LA, Dageforde LA, Swenson BR, et al. Obesity and site-specific nosocomial infection risk in the intensive care unit. *Surg Infect*. 2009;10(2):137–42.
5. Serrano PE, Khuder SA, Fath JJ. Obesity as a risk factor for nosocomial infections in trauma patients. *J Am Coll Surg*. 2010;211(1):61–7.
6. Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. *Obesity*. 2020;28(7):1195–1199.
7. Sakr Y, Madl C, Filipescu D, et al. Obesity is associated with increased morbidity but not mortality in critically ill patients. *Intensive Care Med*. 2008;34(11).
8. Huttunen R, Karpelin M, Syrjänen J. Obesity and nosocomial infections. *J Hosp Infect*. 2013;85(1):8–16.
9. Fantuzzi G. Adipose tissue, adipokines, and inflammation. *J Allergy Clin Immunol*. 2005;115(5):911–9; quiz 920.
10. McGuire TR, Brusnahan SK, Bilek LD, et al. Inflammation associated with obesity: relationship with blood and bone marrow endothelial cells. *Obesity*. 2011;19(11):2130–6.
11. Alipoor E, Mohammad Hosseinzadeh F, Hosseinzadeh-Attar MJ. Adipokines in critical illness: A review of the evidence and knowledge gaps. *Biomed Pharmacother*. 2018;108:1739–1750.
12. Wurzinger B, Dünser MW, Wohlmuth C, et al. The association between body-mass index and patient outcome in septic shock: a retrospective cohort study. *Wien Klin Wochenschr*. 2010;122(1–2):31–6.
13. Bamgbade OA, Rutter TW, Nafiu OO, Dorje P. Postoperative complications in obese and nonobese patients. *World J Surg*. 2007;31(3):556–60; discussion 561.

14. Nair GB, Niederman MS. Ventilator-associated pneumonia: present understanding and ongoing debates. *Intensive Care Med.* 2014;41(1):34–48.
15. Melsen WG, Rovers MM, Groenwold RHH, et al. Attributable mortality of ventilator-associated pneumonia: A meta-analysis of individual patient data from randomised prevention studies. *Lancet Infect Dis.* 2013;13(8):665–671.
16. Martin-Loeches I, Poveda P, Rodríguez A, et al. Incidence and prognosis of ventilator-associated tracheobronchitis (TAVeM): A multicentre, prospective, observational study. *Lancet Respir Med* 2015;3(11).
17. Papazian L, Klompas M, Luyt C-E. Ventilator-associated pneumonia in adults: a narrative review. *Intensive Care Med.* 2020;46(5):888–906.
18. Reignier J, Boisramé-Helms J, Brisard L, et al. Enteral versus parenteral early nutrition in ventilated adults with shock: A randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2). *Lancet* 2017; 391:133-143
19. Brisard L, Gouge A Le, Lascarrou J-B, et al. Impact of early enteral versus parenteral nutrition on mortality in patients requiring mechanical ventilation and catecholamines: study protocol for a randomized controlled trial (NUTRIREA-2)*Trials.* 2014; 15
20. Jaillette E, Girault C, Brunin G, et al. Impact of tapered-cuff tracheal tube on microaspiration of gastric contents in intubated critically ill patients: a multicenter cluster-randomized cross-over controlled trial. *Intensive Care Med.* 2017; ;43:1562-1571
21. Nseir S, Gouge A Le, Lascarrou J-B, et al. Impact of nutrition route on microaspiration in critically ill patients with shock: a planned ancillary study of the NUTRIREA-2 trial. *Crit Care.* 2019;23(1):111.
22. Fine JP GR. A proportional hazards model for the subdistribution of a competing risk. 1999; 94: 496–509. *J Am Stat Assoc* 1999;94:496–509.
23. Frat J-P, Gissot V, Ragot S, et al. Impact of obesity in mechanically ventilated patients: a prospective study. *Intensive Care Med.* 2008;34(11):1991–8.
24. Parmentier-Decrucq E, Nseir S, Makris D, et al. Accuracy of leptin serum level in diagnosing ventilator-associated pneumonia: A case-control study. *Minerva Anesthesiol.* 2014;80(1).
25. Marques MB, Langouche L. Endocrine, metabolic, and morphologic alterations of adipose tissue during critical illness. *Crit Care Med.* 2013;41(1):317–25.

Figure legends

Figure 1

Flowchart

Figure 2

Relationship between obesity and VAP incidence at day 28.

Incidence of VAP at day 28: 8.6% vs 10.1%; HR: 0.845, 95% CI: [0.629; 1.140], p=0.26.

Incidence of ICU death without VAP prior at day 28: 26.0% vs 26.8%; HR: 0.982, 95% CI:

[0.831; 1.160], p=0.83. Incidence of extubation without VAP prior at day 28: 59.8% vs 58.2%;

HR: 1.00, 95% CI: [0.899; 1.110], p=1

Figure 3

Relationship between obesity and duration of mechanical ventilation.

The incidence of extubation at day 28 was 66.1% and 65.2% in obese and non-obese patients, respectively (HR=0.99; CI95%: [0.89; 1.08], p=0.71).

Figure 4

Relationship between obesity and length of ICU stay.

The incidence of ICU-discharge alive at day 28 was 58.4%, and 57.9% in the obese and non-obese patients; respectively (HR=0.99; 95% CI: [0.89; 1.09], p=0.79).

Table 1. Patient characteristics at ICU admission

	Obese (n=699)	Non-obese (n=1626)	p
Gender			0.02
Female	254 (36.3)	512 (31.5)	
Male	445 (63.7)	1114 (68.5)	
Age, years	67.8 [60.4, 75.3]	66.9 [55.9, 77.1]	0.0009
Weight, kg	97.3 [88.0, 110.0]	70.0 [61.0, 79.0]	-
BMI, kg/m ²	34.6 [31.8, 38.6]	24.6 [21.9, 27.0]	-
SAPS II ^a	58.0 [47.0, 74.0]	59.0 [45.0, 73.0]	0.93
McCabe score			0.01
Death expected within 5 years	237 (33.9)	527 (32.4)	
Death expected within 1 year	20 (2.9)	93 (5.7)	
No fatal underlying disease	442 (63.2)	1006 (61.9)	
Knaus score			<0.0001
Normal health status	97 (13.9)	399 (24.5)	
Moderate activity limitation	400 (57.2)	761 (46.8)	
Severe activity limitation due to chronic disease	190 (27.2)	430 (26.4)	
Bedridden patient	12 (1.7)	36 (2.2)	
Type of patients			0.95
Scheduled surgery	10 (1.4)	26 (1.6)	
Urgent surgery	39 (5.6)	93 (5.7)	
Medical	650 (93.0)	1507 (92.7)	
Acute illness at ICU admission			<0.0001
Cardiac arrest	68 (9.7)	184 (11.3)	
Acute heart failure	152 (21.7)	310 (19.1)	
Acute neurologic failure	43 (6.2)	138 (8.5)	
Acute respiratory failure	334 (47.8)	840 (51.7)	
Trauma	10 (1.4)	35 (2.2)	

Miscellaneous	92 (13.2)	119 (7.3)	
Cause of shock			0.97
Cardiac	133 (19.0)	307 (18.9)	
Sepsis	440 (62.9)	1016 (62.5)	
SIRS with noninfectious causes	45 (6.4)	114 (7.0)	
Other	81 (11.6)	189 (11.6)	
Pre-existing illness at ICU admission	530 (75.9)	1162 (71.6)	0.03
Chronic renal failure	111 (15.9)	201 (12.4)	
Liver disease	59 (8.4)	137 (8.4)	
Cardiovascular disease	166 (23.7)	363 (22.3)	
Chronic respiratory failure	128 (18.3)	215 (13.2)	
Neurological disease	88 (12.6)	222 (13.6)	
Diabetes	288 (41.2)	321 (19.7)	
Cancer or immune deficiency	165 (23.6)	515 (31.7)	
Esophageal, gastric, or duodenal ulcer	43 (6.2)	105 (6.5)	

Results are Median [Q1, Q3] or n (%)

BMI, body mass index; SAPS, simplified acute physiology score; ICU, intensive care unit.

^aMissing data: 6, 9; in obese and non obese patients, respectively.

Table 2. Patient characteristics at randomization.

	Obese (n=699)	Non obese (n=1626)	p
PEEP, cmH ₂ O ^a	7.0 (5.0, 10.0)	6.0 (5.0, 9.0)	0.0002
FiO ₂ , %	50.0 (40.0, 70.0)	50.0 (35.0, 70.0)	0.002
Prone position	29 (4.1)	72 (4.4)	0.76
Sedative drugs	601 (86.0)	1406 (86.5)	0.75
Dialysis	138 (19.7)	213 (13.1)	<0.0001
Insulin use	334 (47.8)	583 (35.9)	<0.0001
Prokinetic drugs	11 (1.6)	29 (1.8)	0.72
Anti-ulcer medication	328 (46.9)	658 (40.5)	0.004
Anti-infectious treatment	588 (84.1)	1357 (83.5)	0.69
Glucose, mmol/l ^b	9.7 (7.3, 12.5)	9.0 (6.8, 12.2)	0.002
Creatinine, μmol/L ^c	169.0 (107, 283)	125.4 (80, 209)	<0.0001
Lactate, mmol/l ^d	2.6 (1.6, 4.5)	2.6 (1.6, 4.7)	0.98
CRP, mg/l ^e	137.8 (54.5, 263.7)	140.0 (51.0, 254.5)	0.48
Albumin, g/l ^f	26.2 (21.6, 31.0)	25.0 (20.0, 30.0)	0.001
SOFA ^g	11.0 (9.0, 13.0)	10.0 (8.0, 13.0)	0.0001
Time from intubation to randomization, hour	15.3 (7.8, 20.8)	14.4 (7.3, 20.2)	0.14
Enteral nutrition (group of randomization)	354 (50.6)	805 (49.5)	0.62

Results are median [Q1, Q3] or n (%).

PEEP, positive end expiratory pressure; FiO₂, fraction of inspired oxygen; CRP, reactive C protein; SOFA, sequential organ dysfunction assessment.

Missing data: ^a 1, 4; ^b 70, 181; ^c 5, 16; ^d 20, 68; ^e 299, 626; ^f 235, 679; ^g 1, 0; in obese and non obese patients, respectively.

Table 3. Impact of obesity on secondary outcomes

	Obese (n=699)	Non obese (n=1626)	p
Duration of mechanical ventilation			0.71
Patients alive, n1=498, n2=1136	8 (4, 14)	6 (3, 13)	
Patients dead before extubation, n1=201, n2=490	5 (2, 12)	7 (2, 14)	
ICU length of stay			0.79
Patients alive, n1=473, n2=1061	12 (7, 20)	9 (6, 17)	
Patients dead in the ICU, n1=226, n2=565	6 (2, 15)	8 (3, 15)	
90-day mortality	272/692 (39.3)	718/1605 (44.7)	0.02

Results are Median [Q1, Q3], or n (%)

Table 4. distribution of study patients and patients with ventilator-associated pneumonia based on body mass index

BMI	Number of patients N = 2325	Number of patients with VAP N = 224
<20	203 (8.7)	22/203 (10.8)
20 to <25	690 (29.7)	76/690 (11)
25 to <30	733 (31.5)	66/733 (9)
30 to <35	370 (15.9)	35/370 (9.5)
35 to <40	197 (8.5)	16/197 (8)
≥40	132 (5.7)	9/132 (6.8)

Data are N° (%)







